The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells

Journal of Cellular Physiology

Volumn 223, Issue 1, 2010, Pages 178-186

  Wu, William Ka Kei ^a,b   Sung, Joseph Jao Yui ^a,b   To, Ka Fai ^a,b   Yu, Le ^a   Li, Hai Tao ^a   Li, Zhi Jie ^a   Chu, Kin Man ^c   Yu, Jun ^a,b   Cho, Chi Hin ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR; CASPASE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHYMOTRYPSIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEASOME; SMAD1 PROTEIN; SMAD5 PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION;

ADENOCARCINOMA; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CATHELICIDINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD PROTEINS; STOMACH NEOPLASMS; TIME FACTORS; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75749117540     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22026     Document Type: Article

References (35)

1. Bandholtz L, Ekman GJ, Vilhelmsson M, Buentke E, Agerberth B, Scheynius A, Gudmundsson GH. 2006. Antimicrobial peptide LL-37 internalized by immature human dendritic cells alters their phenotype. Scand J Immunol 63:410-419.
2. Bleuming SA, Kodach LL, Garcia Leon MJ, Richel DJ, Peppelenbosch MP, Reitsma PH, Hardwick JC, van den Brink GR. 2006. Altered bone morphogenetic protein signalling in the Helicobacter pylori-infected stomach. J Pathol 209:190-197.
3. Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten Kate FJ, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, Li L, van den Brink GR. 2007. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res 67:8149-8155.
4. Buckley S, Shi W, Driscoll B, Ferrario A, Anderson K, Warburton D. 2004. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 286:L81-L86.
5. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. 2005. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366:1784-1793.
6. Dürr UH, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758:1408-1425.
7. Franzen A, Heldin NE. 2001. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285:773-781.
8. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782.
9. Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF. 2003. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 125:1613-1625.
10. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, Ståhle-Båckdahl M. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 120:379-389.
11. Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E, Sørensen OE, Weber G, Ståhle M. 2005. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 114:713-719.
12. Houghton J, Wang TC. 2005. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128:1567-1578.
13. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. 1998. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 43:964-970.
14. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. 1997. Smad6 inhibits signalling by the TGF-b superfamily. Nature 389:622-626.
15. Koenig BB, Cook JS, Wolsing DH, Wolsing DH, Ting J, Tiesman JP, Correa PE, Olson CA, Pecquet AL, Ventura F, Grant RA, Chen G, Wrana JL, Massague J, Rosenbaum JS. 1993. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 14:5961-5974.
16. Li X, Li Y, Han H, Miller DW, Wang G. 2006. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc 128:5776-5785.
17. Liu A, Niswander LA. 2005. Bone morphogenetic protein signalling and vertebrate nervous system development. Nat Rev Neurosci 6:945-954.
18. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773.
19. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
20. Miyazono K, Suzuki H, Imamura T. 2003. Regulation of TGF-β signaling and its roles in progression of tumors. Cancer Sci 94:230-234.
21. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE. 2006. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455-2464.
22. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. 1997. Identification of Smad7 a TGFβ-inducible antagonist of TGF-β signaling. Nature 389:631-635.
23. Pardali K, Kowanetz M, Heldin CH, Moustakas A. 2005. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 204:260-272.
24. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. 2006. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761-765.
25. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. 2007. A new role of cathelicidin in ulcerative colitis in mice. Exp Biol Med 232:799-808.
26. Tenderenda M. 2005. A study on the prognostic value of cyclinsD1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res 24:405-414.
27. Wang Q, Wei X, Zhu T, Zhang M, Shen R, Xing L, O'Keefe RJ, Chen D. 2007. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2. J Biol Chem 282:10742-10748.
28. Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SG, van Diest PJ, Albertson DG, Meijer GA. 2003. Determination of amplicon boundaries at 20q132 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol 200:320-326.
29. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. 2004. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 316:100-106.
30. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. 2006. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25:2666-2673.
31. Wu WK, Sung JJ, Le Y, Cho CH. 2008a. Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling. Biochem Biophys Res Commun 371:209-214.
32. Wu WK, Sung JJ, WuYC, Li ZJ, Yu L, Cho CH. 2008b. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol 154:632-638.
33. Yang YH, Wu WK, Tai EK, Wong HP, Lam EK, So WH, Shin VY, Cho CH. 2006. The cationic host defense peptide rCRAMPpromotes gastric ulcer healing in rats. J Pharmacol Exp Ther 318:547-554.
34. Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA, Powell SM. 1999. Allelotype of gastric adenocarcinoma. Cancer Res 59:1437-1441.
35. Zughaier SM, Shafer WM, Stephens DS. 2005. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 7:1251-1262.